AstraZeneca: New HQ And R&D Site Underscore Its U.K. Commitment
This article was originally published in The Pink Sheet Daily
Executive Summary
Design plans for AstraZeneca’s new, purpose-built global headquarters and R&D center being constructed in the university town Cambridge underscore the pure pharma’s commitment to innovative science as a standalone, U.K.-based company, says head of early development Menelas Panaglos.